Bimekizumab

Drug Profile

Bimekizumab

Alternative Names: CDP-4940; UCB-4940

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator UCB
  • Class Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • No development reported Psoriasis

Most Recent Events

  • 07 Feb 2017 Phase-II clinical trials in Ankylosing spondylitis (Adjunctive treatment) in Czech Republic, Canada, Poland (Parenteral) before February 2017 (NCT02963506)
  • 07 Feb 2017 Phase-II clinical trials in Psoriatic arthritis (Adjunctive treatment) in Poland, Hungary, Czech Republic (Parenteral) before February 2017 (NCT02969525)
  • 31 Jan 2017 UCB Biopharma initiates enrolment in a phase II extension trial for Plaque psoriasis in Germany (SC) (EudraCT2016-002934-57)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top